Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Radspherin
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Oncoinvent
Drug class:
Ionizing radiation emitter
Related drugs:
‹
177Lu-satetraxetan-lilotomab (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
177Lu-satetraxetan-lilotomab (4)
ibritumomab tiuxetan (3)
AAA614 (2)
Actinium-225 conjugated to daratumumab (2)
CLR 131 (2)
PNT2002 (2)
225Ac-FL-020 (1)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
TLX66 (0)
iodine I 131 tositumomab (0)
samarium-153 DOTMP (0)
EBTATE (0)
FF21101 (0)
ITM-91 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
186Re (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
Re (0)
›
Associations
News
Trials
Filter by
Latest
5ms
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (clinicaltrials.gov)
P2, N=114, Recruiting, Oncoinvent AS
5 months ago
New P2 trial • Surgery • Metastases
|
Radspherin
9ms
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
P1/2, N=67, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
9 months ago
Enrollment closed
|
Radspherin
9ms
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
P1, N=49, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
9 months ago
Enrollment closed
|
Radspherin
over1year
Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy. (PubMed, Technol Cancer Res Treat)
Our study showed a predominately local rather than systemic inflammatory response to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Radspherin® had overall modest impact on the inflammation.
over 1 year ago
Journal • Surgery
|
IFNG (Interferon, gamma) • CCL4 (Chemokine (C-C motif) ligand 4) • IL1R1 (Interleukin 1 receptor, type I)
|
Radspherin
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login